Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 6.5% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in CRISPR/Cas9-based therapies for genetic diseases, known for its pioneering gene editing techniques.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 6.5% on Jun 11, 2026 13:55

• NTLA stock showed bearish movement recently.
• Concerns arose due to the substantial awarding of stock options and RSUs to various company directors, possibly raising worries about share dilution and downward pressure on stock value.
• Investors may view these equity grants as lack of faith in the company's short-term performance or anticipate upcoming challenges, prompting a sell-off of NTLA stocks.
• Market sentiment appears influenced by perceptions of leadership hedging rather than holding onto shares, potentially signaling caution to investors.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Goff Brian

This article is a Form 4 statement from Intellia Therapeutics, detailing changes in beneficial ownership of securities for Director Brian Goff, as required by the SEC.

https://www.moomoo.com/news/notice/307505294/intellia-therapeutics-4-statement-of-changes-in-beneficial-ownership-of

Intellia (NTLA) director Georgia Keresty receives stock awards and options grant

Intellia Therapeutics director Georgia Keresty received equity compensation, including 9,200 restricted stock units (RSUs) and stock options for 13,300 shares at an exercise price of $12.89 per share. Following these grants, her direct holdings in common stock increased to 41,083 shares. The stock options are set to vest in full either on the first anniversary of the June 9, 2026 grant date or the company's next annual meeting of stockholders.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-ff1dd5f15e40.html

Intellia (NTLA) director awarded RSUs and stock options in new grant

Intellia Therapeutics director William J. Chase received new equity awards on June 9, 2026, comprising 9,200 restricted stock units and stock options for 13,300 shares at an exercise price of $12.89. The stock options vest fully on the earlier of one year from the grant date or the next annual stockholders’ meeting and expire on June 8, 2036. Following this grant, Chase directly holds 143,893 common shares of Intellia.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-3c9b98311aa4.html

Intellia (NTLA) director receives 9,200 RSUs and 13,300 options

Intellia Therapeutics director Frank Verwiel was granted 9,200 restricted stock units (RSUs) and a stock option for 13,300 shares, reflecting new equity awards rather than open-market transactions. Following these grants, Verwiel directly holds 35,148 common shares and the new stock option with an exercise price of $12.89 per share. The option vests on the earlier of one year from the June 9, 2026 grant date or the next annual stockholder meeting and expires on June 8, 2036.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-9db79714028e.html

Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options

Intellia Therapeutics director Fred E. Cohen was granted 9,200 restricted stock units and a stock option for 13,300 shares, according to a recent SEC Form 4 filing. The RSUs increase his direct common stock holdings to 216,653 shares, while the stock option has an exercise price of $12.89 per share and vests fully on the earlier of one year from the June 9, 2026 grant date or the next annual stockholders' meeting, expiring on June 8, 2036. These transactions are compensation-related grants, not open-market trades.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-8502e3800dbb.html

Trending Today

Carnival Corporation ($CCL) Stock Forecast: Up 10.0% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Up 5.1% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.0% Today

Autodesk Inc. ($ADSK) Stock Forecast: Down 6.9% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Up 7.3% Today

Teradyne, Inc. ($TER) Stock Forecast: Up 11.5% Today

Deutsche Bank AG ($DB) Stock Forecast: Up 7.0% Today

Royal Caribbean Cruises Ltd. ($RCL) Stock Forecast: Up 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 8.5% Today

Freeport-McMoRan Inc. ($FCX) Stock Forecast: Up 7.3% Today

Intellia Therapeutics, Inc. Price History

01.05.2026 - NTLA Stock was up 5.4%

• NTLA-2001, Intellia's CRISPR-based treatment for ATTR amyloidosis with cardiomyopathy, successfully met the primary endpoint in a pivotal Phase 3 trial. This positive outcome, showing a significant reduction in mortality and cardiovascular events, has fueled investor optimism and confidence in the company's gene editing therapies.
• The FDA lifting clinical holds on Intellia's candidates, lonvoguran ziclumeran and nexiguran ziclumeran, further contributed to the stock's surge. These regulatory advancements signal progress towards potential commercialization and alleviate uncertainties surrounding the company's in vivo CRISPR programs.
• Despite the positive developments, the need for ongoing clinical success and timely FDA approvals to manage cash burn was highlighted by the company's reliance on equity offerings for funding. This underscores the importance of continued regulatory milestones and successful trial outcomes for sustaining investor interest and financial stability in the future.

05.05.2026 - NTLA Stock was down 6.9%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after the significant surge in stock price following positive Phase 3 trial results and extended cash runway.
• Despite the positive sentiment surrounding the Phase 3 trial results and analyst ratings, the mixed signals on the company's valuation, with some suggesting it is already priced for future growth, might have caused caution among investors.
• The anticipation around the upcoming Phase 3 HAELO trial data release for lonvo-z therapy could have led to heightened volatility and uncertainty in the stock price, prompting some investors to take a step back and reassess their positions.
• The discrepancy between the perceived undervaluation by some analysts and the high price relative to peers based on market multiples may have created a sense of ambiguity among investors, contributing to the bearish movement in NTLA stock today.

05.05.2026 - NTLA Stock was down 9.7%

• Expectations and optimism preceding the Phase 3 results of the lonvo-z study for hereditary angioedema (HAE) likely drove a significant price surge before the announcement.
• Despite initial positivity and strong performance in gene-editing technology, the market response to the actual Phase 3 results may have been negative, potentially falling below expectations.
• Conflicting viewpoints on the company's valuation, with some suggesting it is undervalued while market comparisons suggest a higher price compared to industry peers, could have prompted profit-taking and the bearish movement in the stock price.
• Investors may be reassessing their positions and weighing the potential risks and rewards linked to Intellia Therapeutics, resulting in a sell-off and the bearish movement witnessed today.

09.05.2026 - NTLA Stock was down 6.9%

• Intellia Therapeutics (NTLA) stock witnessed a notable decline in value recently.
• The fluctuation in the market may be linked to varying opinions among analysts concerning the company's growth outlook, despite positive results from the Phase 3 trial of its HAE treatment, lonvoguran ziclumeran.
• Investors seemed apprehensive about the perceived risk associated with the lonvo-z therapy, potentially influenced by recent developments.
• Furthermore, a surge in stock value driven by optimistic expectations for the forthcoming Phase 3 data might have prompted traders to capitalize on profits, contributing to the downward trajectory in the stock's price.

19.04.2026 - NTLA Stock was down 8.3%

• The recent bearish movement in NTLA's stock may be linked to investor concerns about potential dilution following a recent $180 million equity offering, despite an improved net loss reported in Q1 2026.
• Investors are wary of the possibility of further dilution if current cash burn rates persist, despite Intellia Therapeutics' affirmation of a multi-year cash runway and positive developments in its gene-editing pipeline.
• Market sentiment seems influenced by uncertainties surrounding future funding requirements and the trade-off between benefits from capital raising and risks of dilution, as suggested in recent discussions on the company's valuation and financial performance.
• Despite encouraging results from clinical trials and advancements in regulatory milestones, today's downward movement in the stock price may reflect a broader market reassessment of Intellia Therapeutics' growth prospects and valuation, resulting in a temporary decline in share value.

11.05.2026 - NTLA Stock was down 6.5%

• NTLA stock showed bearish movement recently.
• Concerns arose due to the substantial awarding of stock options and RSUs to various company directors, possibly raising worries about share dilution and downward pressure on stock value.
• Investors may view these equity grants as lack of faith in the company's short-term performance or anticipate upcoming challenges, prompting a sell-off of NTLA stocks.
• Market sentiment appears influenced by perceptions of leadership hedging rather than holding onto shares, potentially signaling caution to investors.

02.05.2026 - NTLA Stock was down 5.3%

• The bearish movement in NTLA stock could be attributed to profit-taking by investors after a recent bullish run following positive Phase III results for lonvoguran ziclumeran and the successful pivotal trial for NTLA-2001.
• Despite the positive news, investors may have been concerned about the company's reliance on equity offerings to fund development, leading to a cautious sentiment in the market.
• The market may also be reacting to potential uncertainties surrounding the commercialization timeline of Intellia's CRISPR therapies, as regulatory approvals and clinical success remain crucial factors for the company's growth trajectory.

02.05.2026 - NTLA Stock was down 7.1%

• The bearish movement in NTLA's stock price today could be attributed to profit-taking by investors after a recent surge in the stock following positive Phase III trial results for its CRISPR-based therapy, lonvoguran ziclumeran.
• Despite the successful pivotal trial results for NTLA-2001 in treating ATTR amyloidosis with cardiomyopathy, the market may have reacted negatively due to concerns about the company's ongoing need for equity offerings to fund development, indicating potential dilution for existing shareholders.
• The undervaluation of NTLA highlighted by analysts, despite positive developments, might have also contributed to the bearish sentiment as investors may be cautious about the company's ability to secure strong payer support for expensive gene editing treatments in the future.
• Overall, the market movement in NTLA today reflects a mix of profit-taking, concerns about funding strategies, and uncertainties surrounding the commercialization and market acceptance of its CRISPR-based therapies.

27.04.2026 - NTLA Stock was up 8.2%

• NTLA reported a reduced first-quarter loss, demonstrating improved financial performance compared to the prior year. This improvement has likely contributed to the positive movement in the stock.
• Positive Phase 3 clinical data for lonvo-z in Hereditary Angioedema (HAE) and advancements in other trials have enhanced investor confidence in the company's future prospects, leading to increased interest and a favorable market sentiment.
• Analysts have set a fair value target of $26.70 for the company, suggesting potential undervaluation. This, along with the anticipation of new product launches and a strengthened financial position, likely plays a role in the stock's upward momentum.
• The resolution of the patent infringement lawsuit counterclaims signals the end of legal uncertainties, potentially eliminating a source of concern for investors and further supporting the stock's positive trajectory.

22.04.2026 - NTLA Stock was up 5.6%

• The dismissal of four counterclaims in the BlueAllele patent infringement lawsuit is seen as a positive development for Intellia Therapeutics, reducing legal uncertainties and potential financial liabilities.
• The submission of the CRISPR-based gene editing therapy, nex-z, poses a unique regulatory challenge for the FDA, highlighting the innovative nature of Intellia's technology and its potential market impact.
• Despite concerns about dilution from a recent equity offering, Intellia's improved net loss in Q1 2026 and emphasis on a multi-year cash runway are reassuring investors about the company's financial stability and ability to execute its gene-editing pipeline.
• Investor focus on Intellia's gene-editing pipeline progress, upcoming clinical trial readouts, and regulatory milestones underscores the market's anticipation of potential breakthroughs in the competitive gene-editing landscape, further boosting confidence in the company's growth prospects.

10.05.2026 - NTLA Stock was down 5.5%

• The decrease in NTLA's stock price today could be linked to a notable rise in short interest to 46.78% of the float. This surge in short interest may reflect increasing investor pessimism or concerns about the company's future prospects.
• Despite positive Phase 3 trial outcomes for its hereditary angioedema treatment, lonvoguran ziclumeran, and positive FDA developments, the stock appears to be under downward pressure due to valuation worries. Analysts believe NTLA is undervalued by 49.3% and faces potential valuation risks compared to industry peers.
• The recent equity raise by Intellia Therapeutics is also likely contributing to the current bearish sentiment, as investors may be cautious about potential dilution or the company's efficiency in utilizing the raised capital for future expansion.
• The forthcoming presentation of Phase 3 data for lonvo-z at the European Academy of Allergy & Clinical Immunology Congress 2026 could prove to be an important event for NTLA, potentially influencing investor sentiment and the stock's short-term movement.

04.05.2026 - NTLA Stock was up 18.0%

• NTLA stock surged due to the successful results of its CRISPR-based treatment, NTLA-2001, in a pivotal Phase 3 trial for ATTR amyloidosis with cardiomyopathy, demonstrating a significant reduction in mortality and cardiovascular events.
• The positive Phase III results for its CRISPR therapy, lonvoguran ziclumeran, and the FDA lifting clinical holds on another candidate, nexiguran ziclumeran, also contributed to the stock's rise.
• Analysts view NTLA as undervalued, presenting a potential buying opportunity as the company prepares to release Phase 3 HAELO trial data for lonvo-z, its gene-editing therapy for hereditary angioedema.
• The company's success in advancing its gene-editing therapies towards potential commercialization, alongside ongoing clinical achievements, has boosted investor confidence in NTLA's future prospects, driving the bullish market movement.